<html><head></head><body><h1>Elliotts B Solution</h1><p class="drug-subtitle"><b>Generic Name:</b> sodium chloride, sodium bicarbonate, anhydrous dextrose, magnesium sulfate, potassium chloride, calcium chloride and sodium phosphate<br/>
<b>Dosage Form:</b> intrathecal injection<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li>Side Effects</li>
<li>Professional</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><ul>
<li>Description</li>
<li>Clinical Pharmacology</li>
<li>Indications and Usage</li>
<li>Contraindications</li>
<li>Warnings</li>
<li>Precautions</li>
<li>Adverse Reactions/Side Effects</li>
<li class="ddc-toggle-hidden">Drug Abuse and Dependence</li>
<li class="ddc-toggle-hidden">Overdosage</li>
<li class="ddc-toggle-hidden">Dosage and Administration</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
<li class="ddc-toggle-hidden">References</li>
</ul><h2>Elliotts B Solution Description</h2><p>Elliotts B<span class="Sup">®</span> Solution is a sterile, nonpyrogenic, isotonic solution containing <span class="Bold">no</span> bacteriostatic preservatives. Elliotts B Solution is a diluent for intrathecal administration of methotrexate sodium and cytarabine.</p><p>Each 10 mL of Elliotts B Solution contains:</p><p><br/>
Concentration of Electrolytes:</p><p>The formulae and molecular weights of the ingredients are:</p><p><br/>
<br/>
The pH of Elliotts B Solution is 6.0-7.5, and the osmolarity is 288 mOsmol per liter (calculated).</p><h2>Elliotts B Solution - Clinical Pharmacology</h2><p class="First">Elliotts B Solution provides a buffered salt solution for use as a diluent for the intrathecal administration of methotrexate sodium and cytarabine. It has been demonstrated that Elliotts B Solution is comparable to cere­brospinal fluid in pH, electrolyte composition, glucose content, and osmolarity:</p><p>Comparison of Electrolyte Composition, pH and Nonelectrolytic Constituents of Elliotts B Solution and CSF</p><p class="First"><span class="Bold">Solution</span></p><p class="First"><span class="Bold">Na<span class="Sup">+</span><br/>
mEq/L</span></p><p class="First"><span class="Bold">K<span class="Sup">+</span><br/>
mEq/L</span></p><p class="First"><span class="Bold">Ca<span class="Sup">++</span><br/>
mEq/L</span></p><p class="First"><span class="Bold">Mg<span class="Sup">++</span><br/>
mEq/L</span></p><p class="First"><span class="Bold">HCO<span class="Sub">3</span><span class="Sup">-</span><br/>
mEq/L</span></p><p class="First"><span class="Bold">Cl<span class="Sup">-</span><br/>
mEq/L</span></p><p class="First"><span class="Bold">pH</span></p><p class="First"><span class="Bold">Phosphorus<br/>
mg/dL</span></p><p class="First"><span class="Bold">Glucose<br/>
mg/dL</span></p><p class="First">Cerebrospinal Fluid</p><p class="First">117-137</p><p class="First">2.3-4.6</p><p class="First">2.2</p><p class="First">2.2</p><p class="First">22.9</p><p class="First">113-127</p><p class="First">7.31</p><p class="First">1.2-2.1</p><p class="First">45-80</p><p class="First">Elliotts B Solution</p><p class="First">149</p><p class="First">4.0</p><p class="First">2.7</p><p class="First">2.4</p><p class="First">22.6</p><p class="First">132</p><p class="First">6.0-7.5</p><p class="First">2.3</p><p class="First">80</p><p>The approximate buffer capacity of Elliotts B Solution is 1.1 X 10<span class="Sup">-2</span> equivalents when the challenge solution is 0.01 N HCl and 7.8 X 10<span class="Sup">-3</span> equivalents when the challenge solution is 0.01 N NaOH.<span class="Sup">1</span></p><p>Compatibility studies with methotrexate sodium and cytarabine indicate these drugs are physically compati­ble with Elliotts B Solution.</p><p><br/></p><h2>Indications and Usage for Elliotts B Solution</h2><p class="First">Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.</p><h2>Contraindications</h2><p class="First">None known.<br/></p><h2>Warnings</h2><p class="First">Intrathecal administration of drugs such as methotrexate sodium and cytarabine should be performed by per­sonnel skilled in the technique of lumbar puncture under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. The labeling for methotrexate sodium and cytarabine should be consulted.</p><h2>Precautions</h2><p class="First"><br/></p><h3>General</h3><p class="First">Particular attention should be taken to assure the maintenance of sterile technique throughout the procedure. (See DOSAGE AND ADMINISTRATION.)</p><h3>Carcinogenesis, Mutagenesis, Impairment of Fertility</h3><p class="First">No standard mutagenicity or carcinogenicity studies have been conducted with Elliotts B Solution.</p><h3>Usage in Pregnancy</h3><p class="First">All components of Elliotts B Solution are normal body constituents. Animal reproduction studies have not been conducted with Elliotts B Solution.</p><h2>Adverse Reactions</h2><p class="First">Adverse reactions may occur with any given intrathecal injection due to the chemotherapy or the technique of intrathecal administration.  (See product labeling for methotrexate sodium and cytarabine.)</p><p><br/></p><p>Preservative-free methotrexate sodium and cytarabine should be used to minimize adverse reactions due to preservatives.</p><p><br/></p><p>If an adverse reaction does occur, discontinue the administration, evaluate the patient, institute appropriate therapeutic countermeasures and, if possible, save the remainder of the unused solution(s) for examination.</p><h2>Drug Abuse and Dependence</h2><p class="First">There is no potential for drug abuse or drug dependence.</p><h2>Overdosage</h2><p class="First">Elliotts B Solution is a diluent. In the event of a drug, fluid or solute overload following administration, evalu­ate the patient's condition, and institute appropriate corrective treatment. (See product labeling for methotrexate sodium and cytarabine.)</p><h2>Elliotts B Solution Dosage and Administration</h2><p class="First"><span class="Bold">See product labeling for methotrexate sodium and cytarabine.</span></p><p><br/></p><p>Elliotts B Solution is intended for intrathecal administration only.  Elliotts B Solution does not contain antibac­terial preservatives and introduction of contaminated solutions into the cerebrospinal fluid may have extremely serious consequences. Therefore, administration of intrathecal solutions should be accomplished as soon as possible after preparation.</p><p>A sterile filter-needle should be used to withdraw the contents of the ampule.</p><p><br/></p><p>Intrathecal drug products should be inspected visually for particulate matter and discoloration prior to admin­istration.</p><h3>Preparation and Administration Precautions</h3><p class="First">Elliotts B Solution is a diluent for the cytotoxic anticancer agents, methotrexate sodium and cytarabine. Care should be exercised in the handling and preparation of infusion solutions with these products. (See product labeling for methotrexate sodium and cytarabine.)</p><h2>How is Elliotts B Solution Supplied</h2><p class="First">Elliotts B Solution is available in single-use clear glass ampules, packaged 10 ampules per box.<br/>
<br/>
Store at controlled room temperature, 20º-25ºC (68º-77ºF) [See USP].<br/>
<br/>
<span class="Bold">Preservative Free. </span> Discard unused portion.  Use only if solution is clear and ampule is intact.<br/>
<br/>
<span class="Bold">Distributed by:</span><br/>
Lukare Medical, LLC<br/>
Scotch Plains, NJ 07076<br/>
1-855-752-9317<br/>
www.elliottsbsolution.com</p><h2>REFERENCES:</h2><p class="First">1. Cradock JC, et al. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytara­bine and hydrocortisone sodium succinate.  American Journal of Hospital Pharmacy (1978); 35:402.</p><p>Rev. 10/2015</p><h2>PACKAGING</h2><p class="First"><span class="Bold">Ampule labeling:</span></p><p><br/></p><p><span class="Bold">Box labeling:</span></p><p></p><h2>More about lvp solution</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>Pricing &amp; Coupons</li>
<li>Drug class: intravenous nutritional products</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
<li>Lactated ringer's Intravenous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Ringers &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Dehydration</li>
<li>Peritoneal dialysis</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>